Autobio Diagnostics Co Ltd (603658) - Total Assets
Based on the latest financial reports, Autobio Diagnostics Co Ltd (603658) holds total assets worth CN¥11.73 Billion CNY (≈ $1.72 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Autobio Diagnostics Co Ltd (603658) shareholders funds for net asset value and shareholders' equity analysis.
Autobio Diagnostics Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Autobio Diagnostics Co Ltd's total assets have evolved over time, based on quarterly financial data.
Autobio Diagnostics Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Autobio Diagnostics Co Ltd's total assets of CN¥11.73 Billion consist of 55.1% current assets and 44.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.9% |
| Accounts Receivable | CN¥1.26 Billion | 10.6% |
| Inventory | CN¥1.15 Billion | 9.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥136.09 Million | 1.2% |
| Goodwill | CN¥164.65 Million | 1.4% |
Asset Composition Trend (2011–2024)
This chart illustrates how Autobio Diagnostics Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Autobio Diagnostics Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Autobio Diagnostics Co Ltd's current assets represent 55.1% of total assets in 2024, a decrease from 64.4% in 2011.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, down from 8.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 1.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 10.6% of total assets.
Autobio Diagnostics Co Ltd Competitors by Total Assets
Key competitors of Autobio Diagnostics Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.54 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Shanghai Kinetic Medical Co
SHE:300326
|
China | CN¥3.38 Billion |
|
Eurobio Scientific SA
PA:ALERS
|
France | €259.11 Million |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
|
PULSION Medical Systems SE
MU:PUS
|
Germany | €35.15 Million |
|
Aroa Biosurgery Ltd
AU:ARX
|
Australia | AU$95.27 Million |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
Autobio Diagnostics Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.58 | 2.57 | 4.05 |
| Quick Ratio | 2.13 | 2.18 | 3.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.60 Billion | CN¥3.75 Billion | CN¥3.84 Billion |
Autobio Diagnostics Co Ltd - Advanced Valuation Insights
This section examines the relationship between Autobio Diagnostics Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | CN¥11.88 Billion |
| Market Capitalization | $2.81 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Autobio Diagnostics Co Ltd's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Autobio Diagnostics Co Ltd's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Autobio Diagnostics Co Ltd (2011–2024)
The table below shows the annual total assets of Autobio Diagnostics Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥11.88 Billion ≈ $1.74 Billion |
+2.78% |
| 2023-12-31 | CN¥11.55 Billion ≈ $1.69 Billion |
+10.33% |
| 2022-12-31 | CN¥10.47 Billion ≈ $1.53 Billion |
+13.43% |
| 2021-12-31 | CN¥9.23 Billion ≈ $1.35 Billion |
+13.46% |
| 2020-12-31 | CN¥8.14 Billion ≈ $1.19 Billion |
+91.15% |
| 2019-12-31 | CN¥4.26 Billion ≈ $622.91 Million |
+60.24% |
| 2018-12-31 | CN¥2.66 Billion ≈ $388.74 Million |
+21.45% |
| 2017-12-31 | CN¥2.19 Billion ≈ $320.07 Million |
+20.09% |
| 2016-12-31 | CN¥1.82 Billion ≈ $266.53 Million |
+92.63% |
| 2015-12-31 | CN¥945.56 Million ≈ $138.37 Million |
+45.02% |
| 2014-12-31 | CN¥652.03 Million ≈ $95.41 Million |
+58.87% |
| 2013-12-31 | CN¥410.42 Million ≈ $60.06 Million |
+46.45% |
| 2012-12-31 | CN¥280.25 Million ≈ $41.01 Million |
+42.75% |
| 2011-12-31 | CN¥196.32 Million ≈ $28.73 Million |
-- |
About Autobio Diagnostics Co Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immun… Read more